WebMD
Tarik Hadid, M.D., MPH, MS, FACP, medical oncologist and member of the Phase I Clinical Trials and Thoracic Oncology Multidisciplinary Teams at Karmanos, explained what HER2-mutated non-small-cell lung cancer (NSCLC) is, why it’s important for NSCLC patients to receive genetic testing and the treatment options to treat this rare form of lung cancer.
Read the article here.